Alnylam Issues 2023 Corporate Responsibility Report
Alnylam Issues 2023 Corporate Responsibility Report
Alnylam Issues 2023 Corporate Responsibility Report
Alnylam 發佈 2023 年企業責任報告
May 07, 2024
2024年5月7日
– Highlighted New Disclosures of Company's Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy, Water, and Waste Management Footprint–
— 重點介紹公司對環境影響的新披露——包括有關溫室氣體（GHG）排放、能源、水和廢物管理足跡的多年數據—
– Expanded Alnylam Challengers Global Health Equity Initiative –
— 擴大了 Alnylam Challengers 全球健康公平倡議 —
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take meaningful steps across each of its six corporate responsibility pillars. This year's edition expands data disclosures across each pillar and highlights examples of the company's commitment to ensuring patient access, reducing health inequities, and being a responsible steward of the environment.
馬薩諸塞州劍橋--(美國商業資訊)--2024年5月7日-- Alnylam 製藥公司 領先的RNAi療法公司納斯達克股票代碼：ALNY）今天宣佈發佈其 2023 年企業責任報告。該公司繼續就其六個企業責任支柱採取有意義的措施。今年的版本擴大了每個支柱的數據披露，重點介紹了該公司承諾確保患者就診、減少健康不平等以及成爲負責任的環境管理者的例子。
"As we grow and progress in our quest to realize the promise of RNAi, we continue to expand our leadership and impact as a responsible corporate citizen. I am proud of the broad range of initiatives highlighted in this report, which reflect our efforts to continually increase the value that we contribute to society," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam.
“隨着我們在實現RNAi承諾方面取得的成長和進步，我們將繼續擴大我們作爲負責任的企業公民的領導地位和影響力。我爲這份報告中強調的廣泛舉措感到自豪，這些舉措反映了我們爲不斷增加對社會的貢獻的價值所做的努力。” Alnylam首席執行官伊馮娜·格林斯特里特說。
Key highlights from the 2023 report include:
2023 年報告的主要亮點包括：
- Published new data on Alnylam's environmental impact.
Disclosed and third-party verified multiyear data on scope 1, scope 2, and select scope 3 GHG emissions. Published multiyear data on energy, water and waste management footprint.
- 發佈了有關Alnylam環境影響的新數據。
披露並經第三方驗證的有關範圍 1、範圍 2 和特定範圍 3 溫室氣體排放的多年數據。發佈了有關能源、水和廢物管理足跡的多年數據。
- Expanded partnerships and strategies to support diversity and inclusion within clinical trials.
Joined the Novartis-led Beacon of Hope Initiative, a ten-year collaboration with Historically Black Colleges and Universities (HBCUs) to address root causes of health disparities. Activated strategies to reach underserved communities by developing culturally appropriate clinical trial materials, training clinical trial staff, and improving plain language summaries.
- 擴大合作伙伴關係和戰略，以支持臨床試驗的多元化和包容性。
加入了諾華領導的希望之燈倡議，該計劃與歷史悠久的黑人學院和大學（HBCU）進行了爲期十年的合作，旨在解決健康差異的根本原因。通過開發符合文化背景的臨床試驗材料、培訓臨床試驗人員和改進通俗易懂的語言摘要，激活戰略，以覆蓋服務不足的社區。
- Extended reach of Alnylam Challengers global health equity initiative.
Grew signature social impact program to include 5 countries in which Alnylam has a local presence. Highlighted programmatic impact of partnerships with innovative social entrepreneurs and non-profit organizations working on the frontlines to address health and economic inequalities.
- 擴大了Alnylam Challengers全球健康公平計劃的覆蓋範圍。
擴大了標誌性的社會影響力計劃，將Alnylam在當地開展業務的5個國家包括在內。強調了與在第一線努力解決健康和經濟不平等問題的創新型社會企業家和非營利組織建立夥伴關係所產生的方案影響。
- Shared new employee demographic data and results of pay equity analysis.
Released new employee demographic data and highlighted results of a recent annual pay equity analysis.
- 分享了新員工人口統計數據和薪酬公平分析結果。
發佈了新的員工人口統計數據，並重點介紹了最近的年度薪酬公平分析結果。
To learn more about corporate responsibility at Alnylam, download the full 2023 Corporate Responsibility Report here.
要了解有關Alnylam企業責任的更多信息，請下載完整的《2023年企業責任報告》 這裏。
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
關於 Alnylam 製藥
Alnylam Pharmicals（納斯達克股票代碼：ALNY）已率先將RNA干擾（RNAi）轉化爲一類全新的創新藥物，有可能改變患有罕見和流行病但需求未得到滿足的人們的生活。基於獲得諾貝爾獎的科學，RNAi療法代表了一種強大的、經過臨床驗證的方法，可以產生變革性藥物。自 2002 年成立以來，Alnylam 一直領導 RNAI 革命 並繼續實現將科學可能性變爲現實的大膽願景。Alnylam 的商用 RNAi 治療產品是 ONPATTRO （patisiran）、AMVUTTRA （vutrisiran），GIVLAARI (givosiran)、OXLUMO (lumasiran) 和 Leqvio （inclisiran），由Alnylam的合作伙伴諾華開發和商業化。Alnylam擁有豐富的研究藥物產品線，包括多個處於後期開發階段的候選產品。Alnylam 正在執行其 “Alnylam P5x25" 該戰略旨在通過可持續的創新和卓越的財務業績爲世界各地的患者提供治療罕見病和常見疾病的變革性藥物，從而使生物技術處於領先地位。Alnylam 總部位於馬薩諸塞州劍橋。有關我們的員工、科學和管道的更多信息，請訪問 www.alnylam.com 並在 X（前身爲 Twitter）上與我們互動，網址爲 @Alnylam，或者開啓 領英， Facebook，或 Instagram。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507507791/en/
Alnylam Pharmaceuticals, Inc.
Alnylam 製藥公司
Christine Regan Lindenboom
(Investors and Media)
+1-617-682-4340
克里斯汀·里根·林登布姆
（投資者和媒體）
+1-617-682-4340
Josh Brodsky
(Investors)
+1-617-551-8276
喬什·布羅德斯基
（投資者）
+1-617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
來源：Alnylam Pharmicals, Inc.